AbbVie: all 2,243 studies

Page 14 of 23. Open to participants first (136), then studies with results posted, then the rest; newest registration first within each.

• Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult ParticipantsActive, not recruitingNCT07680686Phase 1
• A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult ParticipantsActive, not recruitingNCT07649954Phase 1
• A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult ParticipantsCompletedNCT07604558Phase 1
• A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular EdemaWithdrawnNCT07604545
• A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nacresertib Moves Through the Body In Healthy Adult Japanese ParticipantsCompletedNCT07600762Phase 1
• A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult ParticipantsCompletedNCT07599761Phase 1
• Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy VolunteersCompletedNCT07587008Phase 1
• A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.CompletedNCT07567781Phase 1
• A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult ParticipantsCompletedNCT07566130Phase 1
• A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.Active, not recruitingNCT07514260Phase 1
• A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female ParticipantsCompletedNCT07502417Phase 1
• A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult ParticipantsCompletedNCT07425899Phase 1
• A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingCompletedNCT07421258
• A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral ContraceptivesCompletedNCT07414784Phase 1
• A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy VolunteersCompletedNCT07413133Phase 1
• Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)Active, not recruitingNCT07387471Phase 2
• A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult ParticipantsCompletedNCT07361367Phase 1
• A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseaseCompletedNCT07284381Phase 3
• A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 InjectionsActive, not recruitingNCT07232004Phase 1
• A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult ParticipantsCompletedNCT07222709Phase 1
• Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II DisorderActive, not recruitingNCT07220460Phase 2
• A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male ParticipantsCompletedNCT07219017Phase 1
• A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial AppearanceCompletedNCT07186595Phase 4
• A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy VolunteersCompletedNCT07141199Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult ParticipantsCompletedNCT07136103Phase 1
• A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite SystemCompletedNCT07122583Phase 4
• Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in ChinaCompletedNCT07058051
• A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult ParticipantsCompletedNCT07032597Phase 3
• An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisActive, not recruitingNCT07027527Phase 1
• Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese ParticipantsCompletedNCT07024797Phase 1
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia AreataActive, not recruitingNCT07023302Phase 3
• A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult ParticipantsCompletedNCT07007091Phase 1
• A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male ParticipantsCompletedNCT06953934Phase 1
• A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult ParticipantsCompletedNCT06946524Phase 1
• A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult ParticipantsCompletedNCT06937619Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With AsthmaActive, not recruitingNCT06920901Phase 1
• A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult ParticipantsCompletedNCT06895356Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian ParticipantsActive, not recruitingNCT06895343Phase 1
• A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult ParticipantsCompletedNCT06887010Phase 1
• A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabActive, not recruitingNCT06880744Phase 3
• A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult ParticipantsCompletedNCT06849791Phase 1
• A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)CompletedNCT06834789Phase 1
• Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineActive, not recruitingNCT06806293Phase 3
• A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult ParticipantsCompletedNCT06794866Phase 3
• A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica ProductsCompletedNCT06783621Phase 4
• A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult ParticipantsCompletedNCT06774313Phase 1
• A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female ParticipantsCompletedNCT06742086Phase 1
• A Study to Assess Change in How Oral Icalcaprant With Itraconazole Moves Through the Body in Healthy Adult ParticipantsCompletedNCT06722430Phase 1
• A Single Dose Study to Assess Adverse Events and How Oral Icalcaprant Moves Through the Body in Healthy Adult Japanese and Han Chinese ParticipantsCompletedNCT06722417Phase 1
• A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic DermatitisActive, not recruitingNCT06718101Phase 2
• Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic DermatitisActive, not recruitingNCT06701331Phase 3
• A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult ParticipantsCompletedNCT06698926Phase 1
• Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In CanadaCompletedNCT06692881
• A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian ParticipantsCompletedNCT06673238Phase 1
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaActive, not recruitingNCT06667687Phase 1
• Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life SettingActive, not recruitingNCT06639620
• Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)Active, not recruitingNCT06632951Phase 2
• A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese VolunteersCompletedNCT06632938Phase 1
• A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaActive, not recruitingNCT06628310Phase 2
• A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive DisorderTerminatedNCT06618118Phase 1
• A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal CancerActive, not recruitingNCT06614192Phase 2
• Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II DisorderCompletedNCT06605599Phase 2
• Expanded Access to FosigotifatorNo longer availableNCT06594016
• A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088TerminatedNCT06579300Phase 1
• A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult ParticipantsCompletedNCT06571266Phase 1
• A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in ChinaActive, not recruitingNCT06548568
• A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin QualityCompletedNCT06547125Phase 2/3
• Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With MigraineActive, not recruitingNCT06543914
• A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart ReviewCompletedNCT06503536
• A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy ParticipantsCompletedNCT06487572Phase 1
• A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedNCT06487559Phase 1
• A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult ParticipantsCompletedNCT06477926Phase 1
• A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06468228Phase 3
• Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal CancerActive, not recruitingNCT06464692Phase 1
• A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic DermatitisActive, not recruitingNCT06461897Phase 3
• Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's DiseaseCompletedNCT06459297
• An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)CompletedNCT06443775
• Expanded Access to ABBV-787No longer availableNCT06439966
• An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)CompletedNCT06439394
• A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male ParticipantsCompletedNCT06435923Phase 1
• An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in ChinaCompletedNCT06421740
• Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineActive, not recruitingNCT06417775Phase 3
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.CompletedNCT06414798Phase 1
• A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy ParticipantsCompletedNCT06406348Phase 1
• A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled SyringeCompletedNCT06402513Phase 1
• A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult ParticipantsCompletedNCT06399718Phase 3
• A Study Evaluating APG777 in Atopic DermatitisActive, not recruitingNCT06395948Phase 2
• A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic DermatitisWithdrawnNCT06390722Phase 3
• A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabActive, not recruitingNCT06389136Phase 3
• A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle ProminenceCompletedNCT06387394Phase 3
• A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult ParticipantsCompletedNCT06366243Phase 1
• A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionActive, not recruitingNCT06365853Phase 2
• A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in JapanCompletedNCT06362044
• A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart ReviewWithdrawnNCT06362031
• A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel DiseaseCompletedNCT06346288Phase 4
• A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult ParticipantsActive, not recruitingNCT06345339Phase 2/3
• A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)CompletedNCT06333860Phase 4
• Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's DiseaseActive, not recruitingNCT06332534Phase 3
• A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT06318273Phase 1
• A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar LinesCompletedNCT06308198Phase 3

← AbbVie overview and focus areas